Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
Balance Sheet
Inspect the capital base behind the business.
Assets
$21.08M
FY 2025 · Annual
+51.4% YoYLiabilities
$4.23M
FY 2025 · Annual
-8.4% YoYEquity
$16.85M
FY 2025 · Annual
+81.0% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $14.2M |
| Other Current | $2.0M |
| Total Current Assets | $16.2M |
| Total Assets | $16.2M |
Analysis
Selected assets total $16.2M for Latest. The largest visible component is Cash & Equivalents at $14.2M, about 87.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEF 14A | DEF 14A filing | Sep 11, 2026 | |
| PRE 14A | PRE 14A filing | Aug 25, 2026 | |
| 10-Q | Quarterly report | Aug 14, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 | |
| 8-K | Current report | Aug 14, 2026 |
How much cash does ANVS have?
Annovis Bio, Inc. (ANVS) reported $19.53M in cash and equivalents in fiscal 2025.
How much debt does ANVS carry?
Annovis Bio, Inc. (ANVS) reported $0.00 of total debt, with net debt of -$19.53M.
Continue the stock analysis
Jump to another research area for this company.